By the quality of evidence, thymosin alpha-1 has the most clinical research (and is approved in some other countries for immune-related uses), KPV has compelling but mostly preclinical data for gut inflammation, and BPC-157 has broad animal evidence across multiple systems
The body interprets rapid fat loss as a significant stressor, releasing inflammatory mediators as part of the adaptive response
Human data for BPC-157 is limited and low-certainty : Small case reports and pilot studies exist, including investigations into knee pain, but these do not rise to the level of large randomized controlled trials
In some embodiments, the otic formulation or composition comprises about 40% by weight of the viscosity modulating agent(s)
It helps send signals of fullness, slows how quickly food leaves the stomach, and may help reduce how much you eat